



MEMORANDUM

TO: Valued STAR and CHIP Providers

FROM: El Paso Health

DATE: 11/28/2023

RE: Change in Preferred Drug List Status for the Macrolides-Ketolides Drug Class Effective Nov. 7, 2023

HHSC is aware of a drug shortage for the brand name Eryped 200 MG/5 ML suspension in the Macrolides-Ketolides drug class.

In response to the shortage of the preferred brand name product Eryped 200 MG/5 ML suspension, HHSC removed the non-preferred status from the generic erythromycin 200 MG/5 ML and E.E.S. 200 MG/5 ML suspension on the preferred drug list (PDL). The preferred status of the brand name Eryped 200 MG/5 ML suspension (NDC 24338013213) will not change to allow for any existing stock available to be utilized.

NDC	Generic Drug Name
62559044001	ERYTHROMYCIN 200 MG/5 ML SUSP
62559044002	ERYTHROMYCIN 200 MG/5 ML SUSP
62559063001	ERYTHROMYCIN 200 MG/5 ML SUSP
69238150301	ERYTHROMYCIN 200 MG/5 ML SUSP
75834029501	ERYTHROMYCIN 200 MG/5 ML SUSP
24338013402	E.E.S. 200 MG/5 ML SUSPENSION
24338013610	E.E.S. 200 MG/5 ML SUSPENSION

These changes will allow providers to prescribe the generic erythromycin 200 MG/5 ML and E. E.S. 200 MG/5 ML suspension without requiring a PDL prior authorization and continue accessing necessary medication for clients.

If you have any questions regarding this communication please contact our Provider Relations team at 915-532-3778 or email us at ProviderRelationsDG@elpasohealth.com